BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 28340220)

  • 1. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
    Solomon JP; Dell'Aquila M; Fadare O; Hasteh F
    Am J Clin Pathol; 2017 Apr; 147(4):432-437. PubMed ID: 28340220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of a Dual (Immunohistochemistry and Fluorescence In Situ Hybridization) HER2/neu Testing Strategy on Invasive Breast Cancers.
    Hariri N; Zare S; Murphy J; Fadare O
    Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):42-48. PubMed ID: 32205742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
    Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With
    Hoda RS; Brogi E; Xu J; Ventura K; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
    Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features.
    Zare SY; Lin L; Alghamdi AG; Daehne S; Roma AA; Hasteh F; Dell'Aquila M; Fadare O
    Hum Pathol; 2019 Jan; 83():7-13. PubMed ID: 30121371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe.
    Zare S; Lin L; Alghamdi AG; Daehne S; Roma AA; Hasteh F; Dell'Aquila M; Fadare O
    Am J Surg Pathol; 2018 Sep; 42(9):1208-1215. PubMed ID: 29923906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.
    Xu FP; Wang K; Xu J; Chen J; Zhang YF; Wu HM; Zhang MH; Long XX; Luo XL; Zhang KP; Lin DY; Liu YH
    Breast Cancer Res Treat; 2017 Dec; 166(3):757-764. PubMed ID: 28861637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-Equivocal HER2 Invasive Breast Carcinomas: Institutional Experience and Review of Literature.
    Griffin BB; Pincus JL; Siziopikou KP; Blanco LZ
    Arch Pathol Lab Med; 2018 Dec; 142(12):1511-1516. PubMed ID: 29595316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
    Shanmugalingam A; Hitos K; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
    Breast Cancer Res Treat; 2023 Feb; 198(1):143-148. PubMed ID: 36604351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer.
    Gajaria PK; Tambe S; Pai T; Patil A; Desai SB; Shet TM
    Indian J Pathol Microbiol; 2020; 63(2):194-199. PubMed ID: 32317514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes.
    Blanton KC; Deal AM; Kaiser-Rogers KA; Anders CK; O'Connor SM; Hertel JD; Calhoun BC
    Ann Diagn Pathol; 2020 Oct; 48():151576. PubMed ID: 32805517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.